TABLE 2.
Demographic clinical characteristics and laboratory data of the patients
| AL κ (n = 18) | AL λ (n = 78) | Controls (n = 48) | ||
|---|---|---|---|---|
| Demographic parameters | Age at diagnosis (IQR) | 67 (62; 74) | 68 (59;76) | 78 (71; 83) |
| Men (%) | 8 (44) | 48 (62) | 36 (75) | |
| Kidney | Median eGFR (IQR) | 51 (33; 69) | 66 (47; 81) | 62 (45; 72) |
| eGFR <60 ml/min/1.73 m2 | 13 (72.2) | 34 (43.6) | 22 (45.8) | |
| Dialysis (%) | 1 (5.6) | 2 (2.5) | 0 (0) | |
| Proteinuria >3 g/24h (%) | 2 (11.1) | 10 (12.7) | 1 (2.1) | |
| Heart | Median cTnT, ng/L (IQR) | 100 (53; 236) | 93 (57; 138) | 43 (23; 78) |
| Median NT‐proBNP, ng/L (IQR) | 7333 (2118–14543) | 6204 (2771–11242) | 1912 (661–3257) | |
| Median strain (IQR) | −9.8 (−13.4; −6.8) | −9.5 (−11.3; −7.6) | −9.6 (−12.0; ‐7.4) | |
| Monoclonal gammopathy | sEP peak (%; median size) | 7 (39; 5 g/L) | 47 (60; 8 g/L) | – |
| Intact monoclonal Ig (%) | 7 (39) | 42 (54) | – | |
| mFLC detection by sIFE (%) | 13 (72.2) | 51 (64.6) | – | |
| Wild‐type TTR amyloidosis (%) | – | – | 28 (58) | |
| Mutated TTR amyloidosis (%) | – | – | 6 (13) | |
| HCM unrelated to amyloidosis/AA amyloidosis (%) | – | – | 14 (29) | |
Note: Data are presented as the median (with interquartile range, IQR) or the number of patients concerned (with percentage of the corresponding cohort). Under monoclonal gammopathy the data presented are: the number of patients with a peak detectable by sEP (with percentage and median value of the peak in g/L), the number of patients with an intact monoclonal immunoglobulin (with percentage), and the number of patients with a monoclonal FLC detectable (with percentage).
Abbreviations: eGFR, estimated glomerular filtration rate by MDRD equation (ml/min/1.73 m2); cTnT, cardiac troponin T; NT‐proBNP, N‐terminal fragment of the prohormone brain‐type natriuretic peptide; sEP, serum electrophoresis; sIFE, serum immunofixation electrophoresis; TTR, transthyretin; HCM, hypertrophic cardiomyopathy; IQR, interquartile range.